A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT06988488
- Locations
- 🇺🇸
Local Institution - 0001, Birmingham, Alabama, United States
🇺🇸Local Institution - 0029, New Haven, Connecticut, United States
🇺🇸Local Institution - 0028, Hackensack, New Jersey, United States
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT06911502
- Locations
- 🇧🇷
Local Institution - 0089, Rio de Janeiro, Brazil
🇧🇷Local Institution - 0092, São Paulo, Brazil
🇨🇦Local Institution - 0226, Sherbrooke, Quebec, Canada
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Conditions
- AgitationAlzheimer Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 120
- Registration Number
- NCT06808984
- Locations
- 🇺🇸
Local Institution - 0057, West Covina, California, United States
🇺🇸Local Institution - 0046, Homewood, Alabama, United States
🇺🇸Local Institution - 0036, Huntsville, Alabama, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Conditions
- Multiple Sclerosis Spasticity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 200
- Registration Number
- NCT06782490
- Locations
- 🇩🇪
Local Institution - 0060, Münster, Nordrhein-Westfalen, Germany
🇵🇱Local Institution - 0048, Oswiecim, MA, Poland
🇵🇱Local Institution - 0047, Warszawa, MZ, Poland
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 960
- Registration Number
- NCT06764485
- Locations
- 🇺🇸
Local Institution - 0330, Birmingham, Alabama, United States
🇺🇸Local Institution - 0329, Gilbert, Arizona, United States
🇺🇸Los Angeles Cancer Network (LACN), Anaheim, California, United States
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT06535399
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Local Institution - 0004, Chandler, Arizona, United States
🇺🇸Local Institution - 0005, Orlando, Florida, United States
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C] BMS-986409 + BMS-986410Drug: [14C] BMS-986410 + BMS-986409Drug: [14C] BMS-986365
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT06433505
- Locations
- 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0152, Birmingham, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT06417229
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT06411730
- Locations
- 🇺🇸
Local Institution - 0001, Anaheim, California, United States